Skip to main content
. 2022 Apr 14;9:847091. doi: 10.3389/fmed.2022.847091

TABLE 3.

Clinical characteristics stratified by DM in patients with low HDLC.

Before propensity score matching
After propensity score matching
Non-diabetes group (n = 218) Diabetes group (n = 59) p-value Non-diabetes group (n = 115) Diabetes group (n = 59) p-value
Sex 1.000 0.753
Male 150 (68.8) 41 (69.5) 84 (73.0) 41 (69.5)
Female 68 (31.2) 18 (30.5) 31 (27.0) 18 (30.5)
Age, years 0.628 1.000
≥60 68 (31.2) 21 (35.6) 40 (34.8) 21 (35.6)
<60 150 (68.8) 38 (64.4) 75 (65.2) 38 (64.4)
BMI, kg/m2 0.169 1.000
≥24.0 94 (43.1) 32 (54.2) 63 (54.8) 32 (54.2)
<24.0 124 (56.9) 27 (45.8) 48 (45.2) 27 (45.8)
Extra-hepatic disease 0.364 0.776
Present 55 (25.2) 19 (32.2) 41 (35.7) 19 (32.2)
Absent 163 (74.8) 40 (67.8) 74 (64.3) 40 (67.8)
Hepatocellular carcinoma 0.556 1.000
Present 74 (33.9) 17 (28.8) 34 (29.6) 17 (28.8)
Absent 144 (66.1) 42 (71.2) 81 (70.4) 42 (71.2)
Triglycerides, mmol/L 0.962 1.000
High 25 (11.5) 6 (10.2) 11 (9.6) 6 (10.2)
Normal 193 (88.5) 53 (89.8) 104 (90.4) 53 (89.8)
ALT, IU/L 0.769 0.996
≥2-fold normal upper limit 50 (22.9) 13 (22.0) 26 (22.6) 13 (22.0)
0–2-fold normal upper limit 39 (17.9) 13 (22.0) 25 (21.7) 13 (22.0)
Normal 129 (59.2) 33 (55.9) 64 (55.7) 33 (55.9)
AST, IU/L 0.923 0.828
≥2-fold normal upper limit 59 (27.1) 16 (27.1) 35 (30.4) 16 (27.1)
0–2-fold normal upper limit 57 (26.1) 14 (23.7) 29 (25.2) 14 (23.7)
Normal 102 (46.8) 29 (49.2) 51 (44.3) 29 (49.2)
MELD score 0.949 0.750
Median 9.0 9.0 9.0 9.0
Interquartile range 6–13 5–14 6–14 5–14
Infection 0.003 0.022
Present 40 (18.3) 22 (37.3) 23 (20.0) 22 (37.3)
Absent 178 (81.7) 37 (62.7) 92 (80.0) 37 (62.7)

Data are presented as the number with percentage or median with interquartile range. ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; DM, diabetes mellitus; HDLC, high-density lipoprotein cholesterol; MELD, model for end-stage liver disease.